Osteoporosis in the elderly
The economic, social and personal burdens of osteoporosis carry a heavy toll. Despite this, it is significantly under-recognized and under-treated. Complete evaluation includes work-up and recognition of secondary causes of osteoporosis in addition to biochemical marker and bone densitometry testing. Recognition of factors contributing to falls is a critical part of prevention of fragility fractures in the elderly. Nutraceutical treatments include calcium and vitamin D. Pharmacologic treatments include bisphosphonates, raloxifene, estrogen, testosterone, strontium ranelate, calcitonin and parathyroid hormone (recombinant 1–34 and 1–84). Although bisphosphonates are generally considered first-line therapy, therapies such as raloxifene and zoledronate have unique benefits. Nonpharmacologic interventions include weight-bearing exercise and behavioral counseling for modification of risk factors such as smoking and alcohol use. Fall and fracture prevention with hip protectors and balance training have also been used. The ideal duration of therapy is not well established. Treatment failure should raise concerns about compliance and secondary causes of fractures/osteoporosis.
Similar entries
- Fractures in the elderly often difficult to heal
- An analysis of the utilisation and expenditure of medicines dispensed for the prophylaxis and treatment of osteoporosis
- NICE issues final guidance on preventing fractures due to osteoporosis
- Osteoporosis common but underestimated in old men: Australian study
- Causes and consequences of rib fractures in older men
- World Osteoporosis Day tomorrow
- Common osteoporosis drugs could make limbs weaker if used for too long
- Booklet aims to prevent falls in elderly: Irish Health
- Osteoporosis treatments denied unless condition worsens
- The Silver Book:Osteoporosis





